Wedbush initiates coverage on Anacor Pharmaceuticals (NASDAQ: ANAC) with a Outperform rating and $13 price target.

The firm said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE